Cyanobacteria represent an underexploited source of bioactive natural products of interest to the pharmaceutical industry. Lack of development of these compounds as drug leads is due mainly to myriad practical problems with the producing strains including long doubling times, genetic intractability, and low compound yields. Previous attempts at heterologous expression...